Cargando…
Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency
BACKGROUND: A well-coordinated adaptive immune response is crucial for limiting COVID-19 disease. Some individuals with immunodeficiency are at a high risk of developing severe COVID-19. Therefore, the development of standardized methods for measuring different arms of the vaccine response in the se...
Autores principales: | Murray, C. E., O’Brien, C., Alamin, S., Phelan, S. H., Argue, R., Kiersey, R., Gardiner, M., Naughton, A., Keogh, E., Holmes, P., Naughton, S., Scanlon, A., Sloan, A., McCrea, P., Sui, J., Dunne, J., Conlon, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080028/ https://www.ncbi.nlm.nih.gov/pubmed/37033955 http://dx.doi.org/10.3389/fimmu.2023.1131604 |
Ejemplares similares
-
Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective
por: King, Catherine, et al.
Publicado: (2021) -
Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health
por: Townsend, Liam, et al.
Publicado: (2021) -
Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
por: Sun, Clare, et al.
Publicado: (2021) -
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency
por: Honjo, Kazuhito, et al.
Publicado: (2020) -
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
por: Wroński, Jakub, et al.
Publicado: (2022)